Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events (AEs) are still scarce. Methods. We conducted a retrospective cohort study including all patients who were prescr...

Full description

Bibliographic Details
Main Authors: Maria Mazzitelli, Daniele Mengato, Lolita Sasset, Anna Ferrari, Samuele Gardin, Vincenzo Scaglione, Nicola Bonadiman, Lucrezia Calandrino, Silvia Cavinato, Sabrina Trivellato, Francesca Venturini, Anna Maria Cattelan
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Viruses
Subjects:
molnupiravir
nirmatrelvir/ritonavir
tolerability
adverse drug reaction
adherence
COVID-19
Online Access:https://www.mdpi.com/1999-4915/15/2/384

Similar Items

Similar Items